Greer Labs and Stallergenes, S.A. Sign Exclusive Agreement for United States Commercialization Rights to Oralair®
ANTONY, France & LENOIR, N.C.--(BUSINESS WIRE)--STALLERGENES S.A. (Euronext Paris), world leader in sublingual immunotherapy and GREER® Laboratories, Inc., a leader in allergy immunotherapy in the United States today announced the signing of an exclusive agreement for the United States commercialization rights to Oralair®, an investigational grass allergy immunotherapy tablet currently under review by the FDA.
Help employers find you! Check out all the jobs and post your resume.